

Appl. No. 10/038,006  
Amdt. dated August 10, 2004  
Reply to Office Action of June 10, 2004

PC 5711-D1-01-CMB


**REMARKS**

Claims 1-3, 16-29 and 31-32 are all the claims under consideration in the application. Claims 1 and 3 have been amended, and Claim 14 cancelled, to limit the pending claims to compounds that fall within the elected species where A = -NCH<sub>2</sub>- . Claim 2 was amended to remove language that does not appear in Claim 1, from which it depends. Applicants reserve the right to pursue the claims covering the cancelled subject matter in a divisional application.

**Election of Species**

In the outstanding office action, the Examiner has required that Applicants elect a single disclosed compound in which all the variables are defined.


Applicants hereby elect 3-(2-Aminomethyl-phenyl)-1-[4-(2,6-dimethyl-piperidin-1-yl)-butyl]-1,3,4,5-tetrahydro-benzo[b][1,4]diazepin-2-one, the structure of which is shown below.



Applicants request prosecution of this application on the merits. The Examiner is encouraged to contact the Applicants' undersigned attorney to discuss this matter if any questions should arise upon further examination of the pending claims.

Respectfully submitted,

Date: March 30, 2004

  
\_\_\_\_\_  
Cynthia M. Bott  
Reg. No. 46,568